drug-reactions
Can spatial proteomics find a TEN therapy?
Open access · cc by · source: Europe PMC
Deep visual proteomics of drug-reaction skin (>5,000 proteins/cell type) revealed interferon–STAT1 programs in TEN; JAK inhibitors improved disease in mouse models.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Inspect source passages
Can spatial proteomics find a TEN therapy?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
More than 5,000 proteins quantified per cell type compartment.
We analysed formalin-fixed, paraffin-embedded archived skin tissue biopsies of three types of cutaneous drug reactions with varying severity and quantified more than 5,000 proteins in keratinocytes and skin-infiltrating immune cells.
Primary DVP cohort n=21 (5 DRESS, 5 MPR, 5 healthy, 6 TEN).
a , Top, schematic of the DVP workflow for cell-type-resolved proteomics in CADRs ( n = 21; 5 each for DRESS, MPR and healthy, and 6 for TEN).
Key findings
TEN showed enriched type I/II interferon signatures and phosphorylated STAT1. Tofacitinib, baricitinib, abrocitinib, or upadacitinib ameliorated clinical/histological severity in mice. TEN involves >30% epidermal detachment and lacked effective therapy.
Methodology
Used deep visual proteomics on archived FFPE biopsies across CADR severities to quantify keratinocyte and immune-cell proteomes, then tested oral JAKis in two TEN mouse models.
Limitations
Mouse efficacy and proteomic nomination are not a completed large randomized TEN trial; dosing/safety in critically ill TEN patients need careful clinical evaluation.
Related papers in this topic
Same topic cluster — not a recommendation engine.